CTOs on the Move

Cartography Biosciences

www.cartography.bio

 
Cartography Biosciences is focused on developing tumor-selective therapeutics that are based on a unique genomics and computational platform. Cartography`s platform integrates data from proprietary sample sourcing relationships, an industry-leading comprehensive reference atlas, and our target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. To learn more about Cartography and our mission to treat every patient with cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cartography.bio
  • 220 East Grand Avenue 2nd Floor
    South San Francisco, CA USA 94080
  • Phone: 833.318.4749

Executives

Name Title Contact Details

Similar Companies

Pronutria

Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated.

Lerner Research Institute

Cleveland Clinic`s rich history includes continuous emphasis on research and innovation. In 1921, the founders stated their commitment not only to treating disease and educating the next generations of healers, but also to researching the causes of disease. They realized that understanding the biological basis of disease is necessary to developing new diagnostics and therapeutics.

Micromet

Micromet, Inc is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.

IFM Therapeutics

At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body`s first line of immunological response and an essential component of immune function.